Women with hereditary angioedema (HAE) see an increase in the number and severity of disease attacks during pregnancy and while breastfeeding, according to a study in Turkey. A normal vaginal delivery without anesthesia was associated with a lower attack rate, leading researchers to argue that in the absence of “special…
People who develop angioedema due to common high blood pressure medications known as angiotensin-converting enzyme (ACE) inhibitors may be at an increased risk of a cardiovascular event in the few months after discontinuing treatment, a study has found. While it’s not clear if switching to an alternative treatment may…
Takhzyro (lanadelumab) may be better than Cinryze at preventing swelling episodes in hereditary angioedema (HAE), according to a study based on data from Phase 3 clinical trials. The study, “Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study,” was published…
A significant proportion of people diagnosed with drug-induced angioedema due to using certain blood pressure medications — namely angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin 2 receptor blockers (ARBs) — were misdiagnosed, according to a recent report from France. These patients, who continued to experience recurrent angioedema attacks more than…
Treatment with Orladeyo (berotralstat) effectively prevented swelling and improved life quality for three people with hereditary angioedema (HAE) with no known disease-causing mutations. “Our results provide the first evidence that [Orladeyo] can be an effective therapy in patients with HAE [who do not have any known mutations],” scientists…
Changes in the properties of endothelial cells that line blood vessels may underlie increases in the numbers of circulating immune neutrophils in people with hereditary angioedema (HAE), according to a recent report. Although neutrophils are more abundant and activated in the blood of people with HAE types 1 and…
Preventive treatment with Takhzyro (lanadelumab) reduced the rate of swelling attacks and improved life quality for Japanese patients with hereditary angioedema (HAE) in a Phase 3 clinical trial. These findings helped to support Takhzyro’s approval in Japan last year for the prevention of swelling attacks in HAE…
Adarx Pharmaceuticals will use $200 million in oversubscribed Series C financing to further develop its clinical programs — including ADX-324, its treatment candidate for hereditary angioedema (HAE) — the clinical-stage biotechnology company announced. The funding round was led by Bain Capital Life Sciences and TCGX, an investment firm…
The U.S. Food and Drug Administration (FDA) has approved a new generic version of Firazyr (icatibant injection) for hereditary angioedema (HAE), Aurobindo Pharma announced in a press release. Like the brand-name medication, the new generic is indicated to treat acute swelling attacks of HAE in adults 18…
Pharvaris has completed patient enrollment for its proof-of-concept CHAPTER-1 clinical trial that will evaluate the safety and effectiveness of deucrictibant as a prophylactic, or preventive, treatment for adults with hereditary angioedema (HAE). While the global Phase 2 CHAPTER-1 study (NCT05047185) is still on hold in the U.S.,…
Get regular updates to your inbox.
